Replies to post #119176 on Biotech Values

[DewDiligence]

There's no question in my mind that Teva is trying to relieve the impact of generic Copaxone.

Yes, all the pieces are falling into place, including Teva’s never mentioning Lovenox again to the investment community (#msg-61955835, third paragraph).